A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 4, 2014, Pages 577-582

  Gitlitz, Barbara J ^a   Bernstein, Eric ^b   Santos, Edgardo S ^c   Otterson, Greg A ^d   Milne, Ginger ^e   Syto, Mary ^f   Burrows, Francis ^f   Zaknoen, Sara ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Providence Cancer Center   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f Tragara Pharmaceuticals   (United States)

Author keywords

Apricoxib; Cyclooxygenase 2 inhibitor; Erlotinib; Non small cell lung cancer; Prostaglandin E2 metabolite

Indexed keywords

APRICOXIB; BIOLOGICAL MARKER; CREATININE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO; PROSTAGLANDIN E2; 7-HYDROXY-5,11-DIOXOTETRANORPROSTANE-1,16-DIOIC ACID; ANTINEOPLASTIC AGENT; PROSTAGLANDIN; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE; TUMOR MARKER;

ABDOMINAL PAIN; ACNE; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BRAIN INFARCTION; CANCER STAGING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRY SKIN; DYSPEPSIA; DYSPNEA; EGFR GENE; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAZARD RATIO; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLITE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH ULCER; TIME TO PROGRESSION; TREATMENT DURATION; TREATMENT RESPONSE; ULCER PERFORATION; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE; URINE; VERY ELDERLY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTAGLANDINS; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; SULFONAMIDES; SURVIVAL RATE;

EID: 84911153353     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000082     Document Type: Article

References (15)

1. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first- line treatment for patients with advanced EGFR mutation-positive non- small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-742.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
3. Csiki I, Johnson DH. Did targeted therapy fail cyclooxygenase too? J Clin Oncol 2006; 24: 4798-4800.
4. Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005; 11: 6097-6099.
5. Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase- 2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 2007; 110: 2775-2784.
6. Kirane A, Toombs JE, Larsen JE, et al. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis 2012; 33: 1639-1646.
7. Kirane A, Toombs JE, Ostapoff K, et al. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res 2012; 18: 5031-5042.
8. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005; 11: 6634-6640.
9. Mutter R, Lu B, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009; 15: 2158-2165.
10. Reckamp K, Gitlitz B, Chen LC, et al. Biomarker-based phase I dose- escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 2011; 117: 809-818.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
13. Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008; 26: 848-855.
14. Csiki I, Johnson DH. Did targeted therapy fail cyclooxygenase too? J Clin Oncol 2006; 24: 4798-4800.
15. Wheatley-Price P. Ding K. Seymour L. Clark G.M. Shepherd F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 2008 26 2350-2357.